AstraZeneca CEO builds up stake
21st Nov 2012 16:34
The Chief Executive Officer of drugs giant AstraZeneca has purchased 3,500 shares in the company, taking his stake in the group to 141,716 shares. Pascal Soriot, who took up his current role just last month, bought the shares at 2,825p each for a total of £98,875. 53-year-old Soriot joined Astra
Read moreLondon close: Stocks finish flat as Eurogroup meets
12th Nov 2012 17:00
- Eyes turn to Eurogroup meeting - Greece approves 2013 budget - Japanese GDP decline worse than feared Concerns about Greece and a worse-than-expected contraction in Japan meant that it was a rather subdued day on the UK stock market on Monday, with the FTSE 100 broadly unchanged by the close. "E
Read moreLondon midday: Stocks rise but markets cautious ahead of Eurogroup
12th Nov 2012 11:36
- Greece approves 2013 budget - Japanese GDP worse than expected - Markets await Eurogroup meeting this afternoon UK stocks were continuing to trade slightly higher on Monday morning after Greece approved its 2013 budget late last night, however, gains were only modest as caution sets in ahead of
Read moreLondon open: Stocks rise as Greece approves budget
12th Nov 2012 08:30
- Greece approves 2013 budget - Japanese GDP worse than expected - Miners fall but Polymetal bucks the trend UK stocks were making gains on Monday morning, rebounding after a 1.7 per cent fall the previous week, as the markets' concerns about the Greek economy eased temporarily. Greece's parliamen
Read moreLondon pre-open: Strong start expected on Greek hopes
12th Nov 2012 07:35
London's FTSE 100 is expected to open positively on Monday morning following tough week which saw the benchmark index lose 1.7 per cent of its value. City sources predict that the Footsie will open with moderate gains from Friday's closing price of 5,770. Newsflow from Greece has lifted sentiment
Read morePositive results for Astra's constipation treatment
12th Nov 2012 07:07
Drugs giant AstraZeneca has announced a clutch of positive test results relating to its naloxegol product, a treatment for opioid-induced constipation (OIC). The results come from two Phase III trials and one safety extension trial in patients with non-cancer related pain and OIC. The Phase III KO
Read moreLondon midday: Stocks lifted by UK GDP and Japanese speculation
25th Oct 2012 11:36
- UK GDP beats expectations in Q3 - Japan to boost asset purchases, says newspaper - Unilever and AstraZeneca provide a lift after Q3 updates After a cautious start, the FTSE 100 was registering decent gains by Thursday lunchtime after UK gross domestic product (GDP) figures showed the country exit
Read moreLondon open: Corporate results impress as markets await GDP data
25th Oct 2012 08:40
- Unilever, AstraZeneca and miners rise after updates - WPP falls after Q3 disappointment - Markets higher ahead of UK GDP UK stocks edged higher on Thursday morning after a flurry of corporate updates were well received; however gains will likely will be modest this morning ahead of the UK growth
Read moreThursday broker round-up - UPDATE
25th Oct 2012 08:20
APR Energy: Seymour Pierce upgrades from reduce to hold, target left at 650p. ASOS: Seymour Pierce raises target from 1,900p to 2,350p, hold rating kept. AstraZeneca: Jefferies keeps hold rating and 3,00p target. Berkeley Group: Goldman Sachs upgrades to conviction buy, target lifted from 1,950p
Read moreAstraZeneca beats expectations despite patent cliff
25th Oct 2012 07:17
AstraZeneca continues to feel the effects of the expiry of patents on key brands, with revenues declining in the third quarter, although it has maintained its core earnings per share (EPS) target, as defined by the company, for the full year. Revenues for the quarter at $6,682m were down 15% at con
Read moreThursday preview: AstraZeneca investors looking for reassurance
24th Oct 2012 16:10
Third-quarter earnings season has got into full swing for UK-listed blue chips with pharmaceuticals giants AstraZeneca and Shire due to report on Thursday, along with consumer product titan Unilever. AstraZeneca will update the market on trading on the three months to the end of September, "traditi
Read moreLondon midday: Markets volatile after mixed economic data
24th Oct 2012 11:19
- Stocks react to mixed economic data - FOMC conclusion eyed - ARM extends gains after Q3 results and SAP statement The FTSE 100 was swinging between gains and loss on Wednesday morning as contrasting economic data from China and the Eurozone painted a mixed picture of the global economy. Markets
Read moreWednesday broker round-up
24th Oct 2012 09:25
African Barrick Gold: Investec raises target from 485p to 530p, hold rating kept. Aggreko: Seymour Pierce maintains buy rating and 2,500p target. AstraZeneca: Panmure Gordon keeps hold rating and 3,000p target. British American Tobacco: Jefferies keeps buy rating and 3,730p target; Panmure Gordon
Read moreWednesday broker round-up - UPDATE
3rd Oct 2012 09:06
African Barrick Gold: Westhouse Secuirites raises target from 464p to 495p. AG Barr: Panmure Gordon keeps hold rating and 440p target. AstraZeneca: Panmure Gordon downgrades from buy to hold, target cut from 3,100p to 3,000p. Barclays: UBS downgrades from buy to neutral, 235p target unchanged. B
Read moreWednesday tips round-up: St.Ives, Workspace, AstraZeneca
3rd Oct 2012 07:03
The Times Tempus column tips St Ives Group, which has moved from the low margin, commoditised world of printing glossy annual reports and magazines. Its print division now produces books and marketing material, such as point of sale displays and posters. This combines well with its second and growin
Read more